-
EP3598974
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3598974
| EP3598974 - TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 07.05.2021 Database last updated on 29.06.2024 | |
| Former | Request for examination was made Status updated on 31.07.2020 | ||
| Former | The application has been published Status updated on 27.12.2019 | Most recent event Tooltip | 20.03.2024 | Change - representative | Applicant(s) | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | [2020/05] | Inventor(s) | 01 /
Dugi, Klaus Boehringer Ingelheim International GmbH, Corporate Patents Binger Strasse 173 55216 INGELHEIM AM RHEIN / DE | 02 /
GRAEFE-MODY, Eva Ulrike Boehringer Ingelheim International GmbH, Corporate Patents Binger Strasse 173 55216 INGELHEIM AM RHEIN / DE | 03 /
HARPER, Ruth Boehringer Ingelheim International GmbH, Corporate Patents Binger Strasse 173 55216 INGELHEIM AM RHEIN / DE | 04 /
WOERLE, Hans-Juergen Boehringer Ingelheim International GmbH, Corporate Patents Binger Strasse 173 55216 INGELHEIM AM RHEIN / DE | [2020/05] | Representative(s) | Hoffmann Eitle, et al Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [N/P] |
| Former [2020/05] | Simon, Elke Anna Maria, et al Boehringer Ingelheim GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | Application number, filing date | 19192328.3 | 05.08.2009 | [2020/05] | Priority number, date | US20080086620P | 06.08.2008 Original published format: US 86620 P | EP20080161989 | 07.08.2008 Original published format: EP 08161989 | EP20080166827 | 16.10.2008 Original published format: EP 08166827 | US200810591508P | 16.10.2008 Original published format: US 10591508 P | [2020/05] | Previously filed application, date | EP20150182960 | 05.08.2009 | [2020/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3598974 | Date: | 29.01.2020 | Language: | EN | [2020/05] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 13.12.2019 | Classification | IPC: | A61K31/40, A61K31/4025, A61K31/403, A61K31/422, A61K31/4375, A61K31/4439, A61K31/4985, A61K31/5025, A61K31/506, A61K31/513, A61K31/522, A61P3/10 | [2020/05] | CPC: |
A61K31/40 (EP,US);
A61K31/4025 (EP,KR,US);
A61K45/06 (US);
A61K31/403 (EP,KR,US);
A61K31/422 (EP,KR,US);
A61K31/427 (EP,US);
A61K31/4375 (EP,KR,US);
A61K31/4439 (EP,KR,US);
A61K31/496 (US);
A61K31/4985 (EP,KR,US);
A61K31/5025 (EP,KR,US);
A61K31/506 (EP,KR,US);
A61K31/513 (EP,KR,US);
A61K31/522 (EP,KR,US);
A61K38/26 (EP);
| C-Set: |
A61K38/26, A61K2300/00 (EP);
A61K38/28, A61K2300/00 (EP) | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2020/36] |
| Former [2020/05] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | BA | 29.07.2020 | RS | 29.07.2020 | Title | German: | DIABETESBEHANDLUNG BEI PATIENTEN, DIE NICHT FÜR DIE METFORMINTHERAPIE GEEIGNET SIND | [2020/05] | English: | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | [2020/05] | French: | TRAITEMENT DU DIABÈTE CHEZ LES PATIENTS NON APPROPRIÉS POUR LA THÉRAPIE AU METFORMINE | [2020/05] | Examination procedure | 29.07.2020 | Examination requested [2020/36] | 29.07.2020 | Date on which the examining division has become responsible | 20.10.2020 | Amendment by applicant (claims and/or description) | 06.05.2021 | Despatch of a communication from the examining division (Time limit: M06) | 07.12.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 16.02.2022 | Reply to a communication from the examining division | 21.11.2024 | Date of oral proceedings | Parent application(s) Tooltip | EP09781529.4 / EP2323650 | EP15182960.3 / EP2990037 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 16.02.2022 | Request for further processing filed | 16.02.2022 | Full payment received (date of receipt of payment) Request granted | 23.02.2022 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 20.10.2020 | Request for further processing filed | 20.10.2020 | Full payment received (date of receipt of payment) Request granted | 03.11.2020 | Decision despatched | Fees paid | Renewal fee | 19.12.2019 | Renewal fee patent year 03 | 19.12.2019 | Renewal fee patent year 04 | 19.12.2019 | Renewal fee patent year 05 | 19.12.2019 | Renewal fee patent year 06 | 19.12.2019 | Renewal fee patent year 07 | 19.12.2019 | Renewal fee patent year 08 | 19.12.2019 | Renewal fee patent year 09 | 19.12.2019 | Renewal fee patent year 10 | 19.12.2019 | Renewal fee patent year 11 | 31.08.2020 | Renewal fee patent year 12 | 31.08.2021 | Renewal fee patent year 13 | 31.08.2022 | Renewal fee patent year 14 | 31.08.2023 | Renewal fee patent year 15 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2007014895 (BOEHRINGER INGELHEIM INT [DE], et al) [A] 1-16* page 25, lines 12-21 *; | [XY]WO2007149797 (NOVARTIS AG [CH], et al) [X] 1-3,7,8,11,12 * abstract * * page 10 * * page 12, paragraph 2 * [Y] 1-16; | [X] - GARBER A J ET AL, "Update: Vildagliptin for the treatment of Type 2 diabetes", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200801 GB, (200801), vol. 17, no. 1, ISSN 1354-3784, pages 105 - 113, XP002508799 [X] 1-3,7,8,11,12 * page 111, column L, paragraph 5.2 * DOI: http://dx.doi.org/10.1517/13543784.17.1.105 | [Y] - ELRISHI M A ET AL, "The dipeptidyl-peptidase-4 (DPP-4) inhibitors: A new class of oral therapy for patients with type 2 diabetes mellitus", PRACTICAL DIABETES INTERNATIONAL 200711 GB, (200711), vol. 24, no. 9, pages 474 - 482, XP002508800 [Y] 1-16 * page 479, column L, paragraph L * * page 479, column R, paragraph 2 * DOI: http://dx.doi.org/10.1002/pdi.1181 | [Y] - DUGI K A ET AL, "BI 1356, a novel xanthine-based DPP-IV inhibitor, exhibits high potency with a wide therapeutic window and significantly reduces postprandial glucose excursions after an oGTT", DIABETOLOGIA, & 43RD ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIAB ETES; AMSTERDAM, NETHERLANDS; SEPTEMBER 18 -21, 2007, (200709), vol. 50, no. Suppl. 1, ISSN 0012-186X, page S367, XP002508801 [Y] 1-16 * the whole document * | [Y] - HUETTNER SILKS ET AL, "BI 1356, a novel and selective xanthine based DPP-IV inhibitor, demonstrates good safety and tolerability with a wide therapeutic window", DIABETES, AMERICAN DIABETES ASSOCIATION, US, (20070601), vol. 56, no. Suppl 1, ISSN 0012-1797, page A156, XP009105519 [Y] 1-16 * the whole document * | [Y] - KANADA SHIGETO ET AL, "Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BI1356 (proposed tradename ONDERO), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes", DIABETES, & 68TH ANNUAL MEETING OF THE AMERICAN-DIABETES-ASSOCIATION; SAN FRANCISCO, CA, USA; JUNE 06 -10, 2008, (200806), vol. 57, no. Suppl. 1, ISSN 0012-1797, pages A158 - A159, XP009110231 [Y] 1-16 * the whole document * | [Y] - GARCIA-SORIA G ET AL, "The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, (20080401), vol. 10, no. 4, doi:10.1111/J.1463-1326.2008.00868.X, ISSN 1462-8902, pages 293 - 300, XP002546703 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1111/J.1463-1326.2008.00868.X | [Y] - O'FARRELL ET AL, "Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, (20070919), vol. 29, no. 8, doi:10.1016/J.CLINTHERA.2007.08.005, ISSN 0149-2918, pages 1692 - 1705, XP022283385 [Y] 1-16 * abstract * DOI: http://dx.doi.org/10.1016/j.clinthera.2007.08.005 | [Y] - ROSENSTOCK J ET AL, "Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, (20070301), vol. 9, no. 2, doi:10.1111/J.1463-1326.2006.00698.X, ISSN 1462-8902, pages 175 - 185, XP002541033 [Y] 1-16 * abstract * DOI: http://dx.doi.org/10.1111/j.1463-1326.2006.00698.x | [YP] - GALLWITZ B, "Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes", IDRUGS, CURRENT DRUGS LTD, GB, (20081201), vol. 11, no. 12, ISSN 1369-7056, pages 906 - 917, XP002546704 [YP] 1-16 * page 912, column l, paragraph l * | by applicant | US5093330 | EP0564409 | WO9835958 | WO0034241 | US6166063 | WO0168603 | WO0214271 | US6395767 | WO02068420 | WO03004498 | WO03037327 | WO2004005281 | US6699871 | WO2004018467 | WO2004018468 | WO2004018469 | WO2004041820 | WO2004046148 | WO2004050658 | WO2004052850 | WO2004111051 | WO2005000848 | WO2005003135 | WO2005047297 | WO2005051950 | WO2005058901 | WO2005063750 | WO2005067976 | WO2005075421 | WO2005082906 | WO2005085246 | WO2005095381 | EP1586571 | WO2005097798 | WO2005106011 | US2005261271 | WO2005110999 | WO2005115982 | WO2005116014 | WO2005117841 | WO2006027204 | WO2006029769 | WO2006040625 | WO2006041976 | WO2006048427 | WO2006068163 | WO2006078593 | WO2006088129 | WO2006100181 | WO2006116157 | WO2006118127 | US2006270701 | WO2006129785 | WO2006135723 | WO2007005572 | WO2007014886 | WO2007019255 | WO2007017423 | US2007060530 | WO2007033266 | WO2007033350 | WO2007035629 | WO2007035372 | WO2007050485 | WO2007071738 | WO2007071576 | WO2007074884 | WO2007112368 | US7291618 | WO2007128721 | WO2007128761 | WO2007128724 | WO2007148185 | US2007299076 | WO2008001195 | WO2008017670 | WO2008027273 | WO2008031749 | WO2008031750 | WO2008033851 | WO2008055814 | WO2008067465 | US2008146818 | WO2008093882 | WO2008109681 | WO2008114807 | WO2008114800 | WO2008114857 | WO2008131149 | WO2008144730 | WO2009009751 | WO2009011451 | WO2009035969 | WO2009084497 | WO2009EP53978 |